Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPECT-2: Eptinezumab for prevention of chronic migraine in adolescents
2024-510656-13-00Phase 3Authorised
- Sponsor
- Lundbeck
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Vyepti (eptinezumab) IV with Placebo IV (2 arms). Primary endpoint: Change From Baseline in Monthly Migraine Days (MMDs) Averaged Over Weeks 1–12. Planned start Nov 2022; status: authorised.
02
Drugs
eptinezumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on 2024-510656-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510656-13-00.